Dr Rau is presently affiliated with Carolina Veterinary Specialists, Greensboro, NC. This study was performed at Tufts University Cummings School of Veterinary Medicine, North Grafton, MA. Preliminary results of this study were presented at the 29th Annual Conference of the Veterinary Cancer Society, October 17, 2009, Austin, TX.
Efficacy of Maropitant in the Prevention of Delayed Vomiting Associated with Administration of Doxorubicin to Dogs
Article first published online: 12 OCT 2010
Copyright © 2010 by the American College of Veterinary Internal Medicine
Journal of Veterinary Internal Medicine
Volume 24, Issue 6, pages 1452–1457, November/December 2010
How to Cite
Rau, S.E., Barber, L.G. and Burgess, K.E. (2010), Efficacy of Maropitant in the Prevention of Delayed Vomiting Associated with Administration of Doxorubicin to Dogs. Journal of Veterinary Internal Medicine, 24: 1452–1457. doi: 10.1111/j.1939-1676.2010.0611.x
- Issue published online: 3 NOV 2010
- Article first published online: 12 OCT 2010
- Submitted March 16, 2010; Revised June 21, 2010; Accepted August 26, 2010.
- 4Acute and short-term toxicoses associated with the administration of doxorubicin to dogs with malignant tumors. J Am Vet Med Assoc 1989;195:1585–1587., , , et al.
- 7Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: Summary of clinical trials. Cancer Invest 2004;24:569–576.
- 11Food and Drug Administration. Freedom of information summary: Cerenia (maropitant citrate) injectable solution for the prevention and treatment of acute vomiting in dogs. NADA #141–263. 2007.
- 12Veterinary Co-operative Oncology Group Common Terminology Criteria for Adverse Events (VCOG-CTCAE). A consensus document from the VCOG. Vet Comp Oncol 2004;2:194–213.
- 17Substance P receptor expression in intestinal epithelium in Clostridium difficile toxin A enteritis in rats. Am J Physiol 1998;275:68–75., , , et al.
- 28ASHP Commission on Therapeutics. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm 1999;56:729–764.